Otsuka Pharmaceutical Co., Ltd. (OTCMKTS:OSUKF) is a Japanese multinational healthcare company headquartered in Tokyo. Founded in 1964, it operates as part of the Otsuka Group and focuses on the discovery, development and commercialization of pharmaceutical and nutraceutical products. Over more than five decades, Otsuka has built a reputation for blending scientific research with patient-focused solutions.
In its pharmaceutical segment, Otsuka specializes in central nervous system disorders, oncology, cardiovascular diseases and metabolic conditions. The company is known for developing and co-marketing innovative therapies such as aripiprazole (brand name Abilify), as well as novel treatments for depression, schizophrenia and bipolar disorder. Its research pipeline includes compounds targeting Alzheimer’s disease and other neurodegenerative disorders.
Otsuka’s nutraceutical arm produces beverage and nutrition products designed to support general well-being. Flagship offerings include Pocari Sweat, an electrolyte-replenishing drink, CalorieMate nutritional bars and SoyJoy soy-based snacks. These products are distributed across Asia, Europe, North America and other regions, reflecting the company’s broad international footprint.
Serving patients and consumers in more than 80 countries, Otsuka maintains a network of R&D centers, manufacturing sites and sales offices worldwide. Guided by a commitment to innovation, ethical practice and sustainable growth, the company continues to pursue strategic partnerships and acquisitions aimed at expanding its global reach and enhancing its pipeline of healthcare solutions.
AI Generated. May Contain Errors.
Free OSUKF Stock Alerts